Non-invasive Bioluminescence Monitoring of Hepatocellular Carcinoma Therapy in an HCR Mouse Model
Animal models play crucial roles in the development of anticancer therapeutics. The ability to quickly assess the localized primary hepatocellular carcinoma (HCC) status in a non-invasive manner would significantly improve the effectiveness of anti-HCC therapeutic studies. However, to date, animal m...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-09-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2019.00864/full |
| _version_ | 1818043690792255488 |
|---|---|
| author | Zhu Zhao Juji Dai Yan Yu Qian Zhang Sai Liu Guanmeng Huang Zheng Zhang Tianke Chen Rulu Pan Liting Lu Wenyi Zhang Wanqin Liao Xincheng Lu |
| author_facet | Zhu Zhao Juji Dai Yan Yu Qian Zhang Sai Liu Guanmeng Huang Zheng Zhang Tianke Chen Rulu Pan Liting Lu Wenyi Zhang Wanqin Liao Xincheng Lu |
| author_sort | Zhu Zhao |
| collection | DOAJ |
| description | Animal models play crucial roles in the development of anticancer therapeutics. The ability to quickly assess the localized primary hepatocellular carcinoma (HCC) status in a non-invasive manner would significantly improve the effectiveness of anti-HCC therapeutic studies. However, to date, animal models with this advantage are extremely scarce. In this study, we developed a novel animal model for the fast assessment of drug efficacy against primary HCC in vivo. HCC was induced in immunocompetent hepatocarcinogenesis reporter (HCR) mice by diethylnitrosamine (DEN) injection and confirmed by histopathological staining. Using the bioluminescence imaging (BLI) technique, HCC progression was longitudinally visualized and monitored in a non-invasive way. Tests of two clinical drugs showed that both sorafenib and oxaliplatin significantly inhibited the BLI signal in mouse liver in a dose-dependent manner. The in vivo intensity of BLI signals was highly consistent with the final tumor burden status in mouse liver after drug treatment. The inhibitory effect of anti-HCC drugs was accurately evaluated through in vivo BLI intensity detection. Our study successfully established a bioluminescence mouse model for non-invasive real-time monitoring of HCC therapy, and this HCR mouse model would be a useful tool for potential anti-HCC drug screening and new therapeutic strategy development. |
| first_indexed | 2024-12-10T09:06:13Z |
| format | Article |
| id | doaj.art-4e85c5fd350c41fe9e8c68f5875665a4 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-10T09:06:13Z |
| publishDate | 2019-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-4e85c5fd350c41fe9e8c68f5875665a42022-12-22T01:55:08ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2019-09-01910.3389/fonc.2019.00864455237Non-invasive Bioluminescence Monitoring of Hepatocellular Carcinoma Therapy in an HCR Mouse ModelZhu ZhaoJuji DaiYan YuQian ZhangSai LiuGuanmeng HuangZheng ZhangTianke ChenRulu PanLiting LuWenyi ZhangWanqin LiaoXincheng LuAnimal models play crucial roles in the development of anticancer therapeutics. The ability to quickly assess the localized primary hepatocellular carcinoma (HCC) status in a non-invasive manner would significantly improve the effectiveness of anti-HCC therapeutic studies. However, to date, animal models with this advantage are extremely scarce. In this study, we developed a novel animal model for the fast assessment of drug efficacy against primary HCC in vivo. HCC was induced in immunocompetent hepatocarcinogenesis reporter (HCR) mice by diethylnitrosamine (DEN) injection and confirmed by histopathological staining. Using the bioluminescence imaging (BLI) technique, HCC progression was longitudinally visualized and monitored in a non-invasive way. Tests of two clinical drugs showed that both sorafenib and oxaliplatin significantly inhibited the BLI signal in mouse liver in a dose-dependent manner. The in vivo intensity of BLI signals was highly consistent with the final tumor burden status in mouse liver after drug treatment. The inhibitory effect of anti-HCC drugs was accurately evaluated through in vivo BLI intensity detection. Our study successfully established a bioluminescence mouse model for non-invasive real-time monitoring of HCC therapy, and this HCR mouse model would be a useful tool for potential anti-HCC drug screening and new therapeutic strategy development.https://www.frontiersin.org/article/10.3389/fonc.2019.00864/fullhepatocellular carcinomaanimal modelhepatocarcinogenesis reporter mousebioluminescence imagingdrug efficacy evaluation |
| spellingShingle | Zhu Zhao Juji Dai Yan Yu Qian Zhang Sai Liu Guanmeng Huang Zheng Zhang Tianke Chen Rulu Pan Liting Lu Wenyi Zhang Wanqin Liao Xincheng Lu Non-invasive Bioluminescence Monitoring of Hepatocellular Carcinoma Therapy in an HCR Mouse Model Frontiers in Oncology hepatocellular carcinoma animal model hepatocarcinogenesis reporter mouse bioluminescence imaging drug efficacy evaluation |
| title | Non-invasive Bioluminescence Monitoring of Hepatocellular Carcinoma Therapy in an HCR Mouse Model |
| title_full | Non-invasive Bioluminescence Monitoring of Hepatocellular Carcinoma Therapy in an HCR Mouse Model |
| title_fullStr | Non-invasive Bioluminescence Monitoring of Hepatocellular Carcinoma Therapy in an HCR Mouse Model |
| title_full_unstemmed | Non-invasive Bioluminescence Monitoring of Hepatocellular Carcinoma Therapy in an HCR Mouse Model |
| title_short | Non-invasive Bioluminescence Monitoring of Hepatocellular Carcinoma Therapy in an HCR Mouse Model |
| title_sort | non invasive bioluminescence monitoring of hepatocellular carcinoma therapy in an hcr mouse model |
| topic | hepatocellular carcinoma animal model hepatocarcinogenesis reporter mouse bioluminescence imaging drug efficacy evaluation |
| url | https://www.frontiersin.org/article/10.3389/fonc.2019.00864/full |
| work_keys_str_mv | AT zhuzhao noninvasivebioluminescencemonitoringofhepatocellularcarcinomatherapyinanhcrmousemodel AT jujidai noninvasivebioluminescencemonitoringofhepatocellularcarcinomatherapyinanhcrmousemodel AT yanyu noninvasivebioluminescencemonitoringofhepatocellularcarcinomatherapyinanhcrmousemodel AT qianzhang noninvasivebioluminescencemonitoringofhepatocellularcarcinomatherapyinanhcrmousemodel AT sailiu noninvasivebioluminescencemonitoringofhepatocellularcarcinomatherapyinanhcrmousemodel AT guanmenghuang noninvasivebioluminescencemonitoringofhepatocellularcarcinomatherapyinanhcrmousemodel AT zhengzhang noninvasivebioluminescencemonitoringofhepatocellularcarcinomatherapyinanhcrmousemodel AT tiankechen noninvasivebioluminescencemonitoringofhepatocellularcarcinomatherapyinanhcrmousemodel AT rulupan noninvasivebioluminescencemonitoringofhepatocellularcarcinomatherapyinanhcrmousemodel AT litinglu noninvasivebioluminescencemonitoringofhepatocellularcarcinomatherapyinanhcrmousemodel AT wenyizhang noninvasivebioluminescencemonitoringofhepatocellularcarcinomatherapyinanhcrmousemodel AT wanqinliao noninvasivebioluminescencemonitoringofhepatocellularcarcinomatherapyinanhcrmousemodel AT xinchenglu noninvasivebioluminescencemonitoringofhepatocellularcarcinomatherapyinanhcrmousemodel |